Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juglans regia leaf hydroalcoholic extract is a botanical preparation derived from the leaves of the walnut tree (Juglans regia L.), typically produced using a 70% ethanol extraction process. It contains a complex mixture of bioactive compounds, including polyphenols, flavonoids such as quercetin-3-O-rhamnoside, and ellagitannins. The extract is primarily studied in academic settings for its anti-inflammatory, antioxidant, and metabolic effects. Its mechanism of action in respiratory conditions involves the upregulation of heme oxygenase-1 (HO-1) and the maintenance of epithelial barrier integrity through increased expression of tight junction proteins, specifically occludin and Zonula occludens-1 (ZO-1). Clinical research has explored its utility in managing cardiovascular risk factors in type 2 diabetes and its protective effects against drug-induced hepatotoxicity and nephrotoxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juglans regia leaf hydroalcoholic extract.